NCT07296445 2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3 Not yet recruiting
Clinical Trials
9 trialsNCT06882031 2025-11-18
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
SDK Therapeutics, Inc.
Phase 1 Completed
NCT04996030 2024-01-23
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Syros Pharmaceuticals
Phase 1 Suspended
NCT03048344 2019-03-25
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Orsenix LLC
Phase 1 Completed
NCT01031368 2019-03-01
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Phase 1 Completed
NCT01902329 2018-01-05
A Safety Study of SGN-CD33A in AML Patients
Seagen Inc.
Phase 1 Completed
NCT01463410 2013-05-29
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Skyline Diagnostics BV
Terminated
NCT00520208 2013-02-13
STAR-1
CytRx
Phase 2 Completed
NCT01018069 2011-07-13
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
Aegera Therapeutics
Phase 2 Terminated